Latest Secondary Hyperparathyroidism (SHPT) News
Intact parathyroid hormone decreased in dialysis patients taking sucroferric oxyhydroxide but increased in those taking sevelamer carbonate.
Study reveals 6-fold higher risk of SHPT in patients on furosemide vs hydrochlorothiazide.
No new safety concerns emerged during the study.
Serum phosphorus and serum creatinine found to be independent predictors of secondary hyperparathyroidism.
The surgery reduced the risk of death from any cause by 37%, meta-analysis shows.
Over 33 months, the 25-hydroxyvitamin D level of ergocalciferol recipients increased significantly from 15.14 to 37.32 ng/mL.
The risk of peripheral arterial disease was 34% lower for end-stage renal disease patients who underwent the procedure.
SHPT risk was 4 times higher among patients taking furosemide vs hydrochlorothiazide.
Researchers highlighted the benefit of iPTH monitoring.
The debate continues on how best to use parathyroidectomy to treat severe SHPT.
Calcifediol formulation is indicated for CKD stage 3 or 4 patients with secondary hyperparathyroidism associated with vitamin D insufficiency.
No new safety concerns observed in a 52-week extension trial of etelcalcetide in hemodialysis with secondary hyperparathyroidism.
Paricalcitol-based protocol includes limited use of calcium-based phosphate binders.
The control of phosphorus is underappreciated, for example.
Researchers found insignificant differences between the 2 surgeries in SHPT persistence and recurrence.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)